Recently, Xuantai Pharmaceutical received a Drug Registration Certificate issued by the National Medical Products Administration, officially approving the marketing of its independently developed "Isaconazole Sulfate for Injection ," bringing new hope for the treatment of fungal infections in China!

Targeting essential clinical needs and enriching the product pipeline

The newly approved isaconazole sulfate for injection is an injectable formulation with a strength of 0.2g (calculated as C₂₂H₁₇F₂N₅OS), indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adults . These two types of infections are serious invasive fungal infections, posing a significant threat to high-risk groups such as those with weakened immune systems, and there is an urgent clinical need for their treatment.

It is understood that the original drug was developed by Pfizer and was quickly included in the National Reimbursement Drug List (NRDL) after being approved in China in June 2022. It has gained widespread clinical recognition due to its clear efficacy and has shown outstanding market performance. According to data from Moshang Pharmaceuticals, its sales reached RMB 204 million in 2024 and RMB 172 million in the first half of 2025, demonstrating strong market potential.

The successful approval of isaconazole sulfate for injection represents a significant step forward for Xuantai Pharmaceutical in the field of anti-infective therapy , further enriching the company's product portfolio and enhancing its overall competitiveness in the treatment of critical infections. This approval also demonstrates the company's solid capabilities in R&D, registration, and production quality management systems, providing valuable experience for subsequent product development and application.

In the future, Xuantai Pharmaceutical will continue to promote market access and channel development for this product, helping more patients gain access to safe and effective treatment options. The company will continue to uphold its values of "producing quality medicines for the benefit of all," accelerating the research and development and launch of more high-quality drugs, and contributing Xuantai's strength to public health.
https://bydrug.pharmcube.com/news/detail/6c8016857baf664705c7a9c7616f8a7e